Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The investigators know that metformin works at the level of the cells in the body by acting
on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding
protein or Constitutive Reverter of eIF2α Phosphorylation (CREP) Binding Protein (CBP). What
the investigators do not know is how this process is affected when the dose of the metformin
is increased or changed.
Currently the same doses of metformin are often used in both children and adults, but it is
possible that the dose of metformin should be based on age and weight. Understanding how CBP
works could potentially help us to tailor metformin treatment individually for patients based
on their age, weight and CBP response.